BRPI0921359A2 - Antígenos que induzem a resposta imunológica contra flavivírus e métodos de uso dos mesmos - Google Patents

Antígenos que induzem a resposta imunológica contra flavivírus e métodos de uso dos mesmos

Info

Publication number
BRPI0921359A2
BRPI0921359A2 BRPI0921359-7A BRPI0921359A BRPI0921359A2 BR PI0921359 A2 BRPI0921359 A2 BR PI0921359A2 BR PI0921359 A BRPI0921359 A BR PI0921359A BR PI0921359 A2 BRPI0921359 A2 BR PI0921359A2
Authority
BR
Brazil
Prior art keywords
antigens
induce
methods
immune response
response against
Prior art date
Application number
BRPI0921359-7A
Other languages
English (en)
Inventor
Ramanathan P Mathura
Niranjan Y Sardesai
Original Assignee
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio Pharmaceuticals Inc filed Critical Inovio Pharmaceuticals Inc
Publication of BRPI0921359A2 publication Critical patent/BRPI0921359A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BRPI0921359-7A 2008-11-17 2009-11-17 Antígenos que induzem a resposta imunológica contra flavivírus e métodos de uso dos mesmos BRPI0921359A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11553508P 2008-11-17 2008-11-17
PCT/US2009/064726 WO2010057159A2 (en) 2008-11-17 2009-11-17 Antigens that elicit immune response against flavivirus and methods of using same

Publications (1)

Publication Number Publication Date
BRPI0921359A2 true BRPI0921359A2 (pt) 2015-08-25

Family

ID=42170795

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921359-7A BRPI0921359A2 (pt) 2008-11-17 2009-11-17 Antígenos que induzem a resposta imunológica contra flavivírus e métodos de uso dos mesmos

Country Status (9)

Country Link
US (1) US8961994B2 (pt)
EP (1) EP2358733B1 (pt)
JP (1) JP5763541B2 (pt)
KR (1) KR101667069B1 (pt)
CN (2) CN102292345B (pt)
AU (1) AU2009313714B2 (pt)
BR (1) BRPI0921359A2 (pt)
CA (2) CA2740598C (pt)
WO (1) WO2010057159A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX346784B (es) * 2010-11-12 2017-03-31 Inovio Pharmaceuticals Inc Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
EP3760227A1 (en) 2011-02-11 2021-01-06 The Trustees of the University of Pennsylvania Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
US9238679B2 (en) * 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
JP6567824B2 (ja) * 2011-10-12 2019-08-28 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
CA2858884A1 (en) 2011-12-12 2013-06-20 The Trustees Of The University Of Pennsylvania Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections
KR20220012403A (ko) * 2012-04-12 2022-02-03 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법
CN114181961A (zh) 2013-03-12 2022-03-15 宾夕法尼亚大学理事会 用于人乳头状瘤病毒的改进疫苗及其使用方法
EP2968509A4 (en) * 2013-03-15 2016-03-23 Univ Pennsylvania MONO OR MULTIVALENT BOTULINUM NEUROTOXIN VACCINE USING THE CLOSTRIDIUM BOTULINUM SERROTYPES HEAVY CHAIN
EP3607974A1 (en) 2013-03-15 2020-02-12 The Trustees of The University of Pennsylvania Cancer vaccines and methods of treatment using the same
ITRM20130458A1 (it) 2013-08-05 2015-02-05 Internat Ct For Genetic En Gineering And Vaccino genetico anti-dengue virus basato sugli ectodomini della proteina envelope
JP7012365B2 (ja) * 2016-02-25 2022-03-04 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ジカウイルスに対する新規のワクチン
CN109071610A (zh) * 2016-05-03 2018-12-21 无微华斯生物科技有限公司 用于诊断和治疗病毒感染的方法和系统
WO2018053478A1 (en) 2016-09-19 2018-03-22 Weiner, David Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus
JP6795468B2 (ja) * 2017-07-14 2020-12-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
US11549125B2 (en) * 2017-08-09 2023-01-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Closed-ended, linear, duplex adenoassociated virus DNA, and uses thereof
JP7075130B2 (ja) * 2019-10-25 2022-05-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
CN114573668B (zh) * 2020-11-30 2023-06-02 中国人民解放军军事科学院军事医学研究院 一种乙脑病毒样颗粒及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0681483T3 (da) 1993-01-26 2005-11-21 Univ Pennsylvania Præparater og fremgangsmåder til administration af genetisk materiale
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
JP4371343B2 (ja) * 1998-10-05 2009-11-25 財団法人阪大微生物病研究会 日本脳炎ウイルス群感染症に対する不活化ワクチンのための増強免疫原およびその製造方法
CN1549730A (zh) * 2000-10-04 2004-11-24 ���������Ǵ�ѧ�й��� 黄病毒和瘟病毒衣壳蛋白的组成和使用方法
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
TWI290174B (en) 2002-11-04 2007-11-21 Advisys Inc Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
DK1628749T3 (da) 2003-05-30 2019-09-16 Vgxi Inc Anordninger og fremgangsmåder til biomateriel produktion
US7060280B2 (en) * 2003-06-11 2006-06-13 Academia Sinica Immunization against flavivirus
AU2005295438B2 (en) * 2004-10-20 2012-07-05 Sanofi Pasteur Biologics, Llc Vaccines against Japanese encephalitis virus and West Nile virus
CA2592005A1 (en) * 2004-12-24 2006-06-29 The Research Foundation For Microbial Diseases Of Osaka University Attenuated chimeric flavivirus bearing attenuated japanese encephalitis virus gene as backbone
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
US20080044808A1 (en) 2006-08-15 2008-02-21 Qian-Li Song West nile virus antigen and assay
PT2066399T (pt) * 2006-10-17 2019-01-11 Inovio Pharmaceuticals Inc Dispositivos de eletroporação e métodos de usar os mesmos para eletroporação de células em mamíferos
CN101096680A (zh) * 2007-05-31 2008-01-02 中国人民解放军军事医学科学院基础医学研究所 一种dna疫苗真核表达载体及其在制备基因疫苗中的应用
TWI445547B (zh) * 2007-06-08 2014-07-21 Nat Health Research Institutes 登革熱病毒胜肽疫苗及其製備與使用方法
EP2209490A4 (en) * 2007-11-14 2013-01-09 VGX Pharmaceuticals LLC ANTIBODY PRODUCTION CAUSED BY DNA VACCINE DELIVERED BY ELECTROPORATION

Also Published As

Publication number Publication date
AU2009313714B2 (en) 2016-05-19
EP2358733A2 (en) 2011-08-24
CA2740598A1 (en) 2010-05-20
EP2358733B1 (en) 2015-07-08
AU2009313714A1 (en) 2010-05-20
KR101667069B1 (ko) 2016-10-17
JP5763541B2 (ja) 2015-08-12
CA3001374A1 (en) 2010-05-20
CN102292345A (zh) 2011-12-21
US20110262394A1 (en) 2011-10-27
WO2010057159A3 (en) 2010-07-08
JP2012509067A (ja) 2012-04-19
US8961994B2 (en) 2015-02-24
EP2358733A4 (en) 2013-01-23
CN102292345B (zh) 2015-12-02
CA2740598C (en) 2018-05-22
CN105400798A (zh) 2016-03-16
WO2010057159A2 (en) 2010-05-20
KR20110086610A (ko) 2011-07-28

Similar Documents

Publication Publication Date Title
BRPI0921359A2 (pt) Antígenos que induzem a resposta imunológica contra flavivírus e métodos de uso dos mesmos
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BRPI0821658A2 (pt) Anticorpos contra nkg2d humano e usos dos mesmos
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BR112013015592A2 (pt) dericados de biciclo-[3.2.1]-octilamida e usos dos mesmos
BRPI0914319A2 (pt) anticorpos estáveis e solúveis que inibem tnfalfa
BRPI0909684A2 (pt) unidade que usa os e aparelho formador de imagem que usa o mesmo
BRPI1011404A2 (pt) mutantes e usos dos mesmos
DK1891953T3 (da) Sterile formuleringer og fremgangsmåder der modificerer immunresponset
BRPI0812856A2 (pt) Composições de vacina de emulsão que compreendem antígeno e adjuvante na fase aquosa.
ZA200906753B (en) Oil-in-water emulsion influenza vaccine
DK2086582T3 (da) Vaccine omfattende en olie-i-vand-emulsionsadjuvans
BR112015002790A2 (pt) anticorpos asgpr e usos dos mesmos.
ZA201004478B (en) Antibodies against influenza virus and methods of use thereof
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI0919412A8 (pt) composição imunonutricional e nutricional,agente intensificador de resposta imunológica e uso do mesmo.
FR2902699B1 (fr) Dispositif de butee de suspension et jambe de force.
BRPI0913656A2 (pt) anticorpos anti-cdh3 marcados com marcador radioisótopo e usos dos mesmos
BRPI0923507A2 (pt) motor e dispositivo elétrico que usa o mesmo.
BRPI0814599A2 (pt) Pesticidas e usos dos mesmos
IT1394876B1 (it) "mezzi per la duplicazione di una chiave codificata elettronicamente e relativo procedimento di duplicazione"
BR112013014235A2 (pt) anticorpos anti-ccr4 e usos dos mesmos
BRPI0913175A2 (pt) artigo antibalístico, e, uso do mesmo.
BRPI0915527A2 (pt) pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements